Conclusions
This study demonstrated that schizophrenia and MDD were inflammatory disorders because enhanced IL-6, TNF-α, and IL-1β levels showed direct links to symptom intensity in affected patients. The higher levels of inflammation observed in schizophrenia patients indicated that microglial dysfunction played a significant role in schizophrenia development than in depression cases. The results emphasized the crucial need to use neuroimmune biomarkers both in psychiatric diagnostic approaches and decision-making in treatment development.
Discovering patterns of psychiatric disorders against inflammation would lead to better intervention strategies, especially when emphasizing neuroinflammation treatments. The obtained information presented opportunities to advance both immunopsychiatric research and clinical mental health treatment effectiveness.